The Effects of Long-Term Oral Benfotiamine Supplementation on Peripheral Nerve Function and Inflammatory Markers in Patients With Type 1 Diabetes: A 24-month, double-blind, randomized, placebo-controlled trial

Diabetes Care, 04/06/2012

The findings suggest that high–dose benfotiamine (300 mg/day) supplementation over 24 months has no significant effects upon peripheral nerve function or soluble markers of inflammation in patients with type 1 diabetes.


  • The study randomly assigned 67 patients with type 1 diabetes to receive 24–month benfotiamine (300 mg/day) or placebo supplementation.
  • Peripheral nerve function and levels of soluble inflammatory variables were assessed at baseline and at 24 months.
  • Fifty–nine patients completed the study.


  • Marked increases in whole–blood concentrations of thiamine and thiamine diphosphate were found in the benfotiamine group (both P < 0.001 vs. placebo).
  • However, no significant differences in changes in peripheral nerve function or soluble inflammatory biomarkers were observed between the groups.

Print Article Summary Cat 2 CME Report